Vincent Aurentz

Vincent Aurentz (senior executive) discloses dealings in 2 companies, chiefly Arena Pharmaceuticals Inc and Inhibikase Therapeutics, Inc. The record holds 3 filings, for trades running from 3 January 2022 to 21 February 2026.

None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.

Most recently, on 24 February 2026, the filings show a transaction in Inhibikase Therapeutics, Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.